Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single intravenous dose of vortioxetine at initiation of oral vortioxetine in major depressive disorder
2018-000992-34Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing IV vortioxetine 25 mg + oral vortioxetine 10 mg/day with IV placebo + oral vortioxetine 10 mg/day (2 arms). Primary endpoint: Change in MADRS-6 subscale score at 24 hours. Started Aug 2018; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-000992-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000992-34.